This paper, co-authored by European psychedelic researchers as well as European Medicines Agency representatives was recently published. It outlines key knowledge gaps “that may be imperative for a successful implementation of psychedelic drugs as medicines”. It provides a summary of topics discussed at the European College of Neuropsychopharmacology at the New Frontiers Meeting in Nice and paves the way for the upcoming EMA workshop on psychedelics.
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
Previous
Previous
PAREA EU Insights February 2024
Next
Next

